Literature DB >> 25332972

The significance of genetics for cholangiocarcinoma development.

Luca Maroni1, Irene Pierantonelli1, Jesus M Banales1, Antonio Benedetti1, Marco Marzioni1.   

Abstract

Cholangiocarcinoma (CCA) is a rare malignancy of the liver, arising from bile ducts. The incidence is increasing worldwide, but the prognosis has remained dismal and virtually unchanged in the past 30 years. Although several risk factors have been associated with the development of this cancer, none of them are normally identified in most patients. Diagnosis in advanced stages of the disease and limited therapeutic options contribute to poor survival rates. The recent analysis of genetic and epigenetic alterations occurring in CCA has shed new light in the understanding of the molecular mechanisms leading to the malignant transformation of biliary cells. Further studies in this direction may foster new diagnostic, prognostic and therapeutic approaches. This review provides a global overview of recent advances in CCA and describes the most important genetic mutations and epigenetic alterations so far reported in CCA.

Entities:  

Keywords:  Genetics; cholangiocarcinoma (CCA)

Year:  2013        PMID: 25332972      PMCID: PMC4200671          DOI: 10.3978/j.issn.2305-5839.2012.10.04

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  171 in total

Review 1.  Early detection and treatment of cholangiocarcinoma.

Authors:  G J Gores
Journal:  Liver Transpl       Date:  2000-11       Impact factor: 5.799

Review 2.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

Review 3.  Transposons reanimated in mice.

Authors:  Timothy H Bestor
Journal:  Cell       Date:  2005-08-12       Impact factor: 41.582

4.  Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis.

Authors:  A M Rijken; J Hu; E J Perlman; L A Morsberger; P Long; S E Kern; R H Hruban; C J Yeo; C A Griffin
Journal:  Genes Chromosomes Cancer       Date:  1999-11       Impact factor: 5.006

5.  Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States.

Authors:  Luciana McLean; Tushar Patel
Journal:  Liver Int       Date:  2006-11       Impact factor: 5.828

6.  Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Naru Kondo; Ryutaro Sakabe; Hiroki Ohge; Taijiro Sueda
Journal:  Ann Surg Oncol       Date:  2010-10-14       Impact factor: 5.344

7.  The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma.

Authors:  Lei Chen; He-Xin Yan; Wen Yang; Liang Hu; Le-Xin Yu; Qiong Liu; Liang Li; Dan-Dan Huang; Jin Ding; Feng Shen; Wei-Ping Zhou; Meng-Chao Wu; Hong-Yang Wang
Journal:  J Hepatol       Date:  2008-11-21       Impact factor: 25.083

Review 8.  c-Met targeted therapy of cholangiocarcinoma.

Authors:  Matei-P Socoteanu; Frank Mott; Gianfranco Alpini; Arthur-E Frankel
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

Review 9.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

Review 10.  The DNA damage response and cancer therapy.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

View more
  14 in total

Review 1.  Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis.

Authors:  Gábor Lendvai; Tímea Szekerczés; Idikó Illyés; Réka Dóra; Endre Kontsek; Alíz Gógl; András Kiss; Klára Werling; Ilona Kovalszky; Zsuzsa Schaff; Katalin Borka
Journal:  Pathol Oncol Res       Date:  2018-11-17       Impact factor: 3.201

2.  The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.

Authors:  Samuel C Fehling; Aubrey L Miller; Patrick L Garcia; Rebecca B Vance; Karina J Yoon
Journal:  Cancer Lett       Date:  2019-10-09       Impact factor: 8.679

Review 3.  Cholangiocarcinoma: from molecular biology to treatment.

Authors:  Ana F Brito; Ana M Abrantes; João C Encarnação; José G Tralhão; Maria F Botelho
Journal:  Med Oncol       Date:  2015-10-01       Impact factor: 3.064

Review 4.  Perioperative Management of Hilar Cholangiocarcinoma.

Authors:  Katherine E Poruk; Timothy M Pawlik; Matthew J Weiss
Journal:  J Gastrointest Surg       Date:  2015-05-29       Impact factor: 3.452

Review 5.  Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma.

Authors:  Sergio A Gradilone; Maria J Lorenzo Pisarello; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

6.  A Case Report of CHEK2 and MUTYH Germline Mutations Associated With Cholangiocarcinoma in a Young Patient.

Authors:  Obaid Rehman; Bradley Sackfield; Viveksandeep Thoguluva Chandrasekar; Jorge Oliver; Ganesh Aswath
Journal:  Cureus       Date:  2022-02-26

7.  In vitro and in vivo study of GSK2830371 and RG7388 combination in liver adenocarcinoma.

Authors:  Chiao-En Wu; Chiao-Ping Chen; Yi-Ru Pan; Shih-Ming Jung; John Wen-Cheng Chang; Jen-Shi Chen; Chun-Nan Yeh; John Lunec
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

8.  Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma.

Authors:  Asmaa Mosbeh; Khalil Halfawy; Wael S Abdel-Mageed; Dina Sweed; Mohamed H Abdel Rahman
Journal:  Cancer Genet       Date:  2018-04-09

9.  ZHX1 Promotes the Proliferation, Migration and Invasion of Cholangiocarcinoma Cells.

Authors:  Ryuk-Jun Kwon; Myoung-Eun Han; Ji-Young Kim; Liangwen Liu; Yun-Hak Kim; Jin-Sup Jung; Sae-Ock Oh
Journal:  PLoS One       Date:  2016-11-11       Impact factor: 3.240

Review 10.  Immune-Mediated Therapies for Liver Cancer.

Authors:  Rajagopal N Aravalli; Clifford J Steer
Journal:  Genes (Basel)       Date:  2017-02-17       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.